Market Research Report
GLOBAL DIABETES DRUGS MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||618296|
|Published||Content info||120 Pages
Delivery time: 1-2 business days
|GLOBAL DIABETES DRUGS MARKET FORECAST 2018-2026|
|Published: April 9, 2018||Content info: 120 Pages||
The global diabetes drug market is mainly being driven by rising obesity amongst the population, growing elderly population and advancements in the insulin technology. Over the forecast years of 2018-2026, the global diabetes drugs market is expected to evolve further at a 6.49% CAGR.
The global diabetes drugs market is segmented on the basis of product class and diabetes type. The product class is further sub-segmented into insulin and non-insulin. The insulin product class includes long-acting, intermediate-acting and fast acting insulin, whereas the non-insulin class includes DPP-4 inhibitors, SGLT-2 inhibitors and GLP-1 receptors agonists. By diabetes type, the global diabetes drugs market is segmented into type 1 and type 2 diabetes.
Regionally, the global diabetes drugs market is segmented into Asia Pacific, Europe, North America and rest of the world. Presently the North American region dominates the global diabetes drugs market. A high obesity rate in the region is increasing the risk of diabetes in the region. By the end of the forecast period, the Asia-Pacific market is expected to showcase the highest CAGR. Emerging countries in this region hold much promise due to big market players due to a huge patient pool of underserved patients.
Some of the key companies engaged in this market are AstraZeneca Plc, Eli Lilly And Company, B.Braun Melsungen Ag, Novo Nordisk A/S, Sanofi, Diavacs Inc, Xoma Corp, Albireo Pharma Inc, Macrogenics Inc, Astellas Pharma, GlaxoSmithKline, Merck, Pfizer, Xeris Pharmaceuticals